Gilead, Re­gen­eron, As­traZeneca and more en­cour­age FDA to ex­pand pa­tient re­port­ed out­come guid­ance

More than a half dozen top drug­mak­ers re­cent­ly called on the FDA to ex­pand its think­ing on pa­tient re­port­ed out­comes in can­cer tri­als to in­clude …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.